CXCL13 and ovarian cancer: Studies have shown that CDK4/6 inhibition combined with PD-1 blockade treatment has higher CXCL10 and CXCL13 levels and CD8 + and CD4 + T cell activity than monotherapy-treated ovarian cancer [27].